J&J CFO ‘Agnostic’ on Size of M&A, Looks at Deals in All Areas

  • CFO says licensing deals preferred for pharma division
  • ‘Very hard to do something transformational for J&J,’ he says

Johnson & Johnson will consider deals of any size and for any of its three main businesses, chief financial officer Dominic Caruso said, though when it comes to pharmaceuticals the company is more interested in less-risky licensing agreements.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.